Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Liabilities: 2021-2023

Historic Other Non-Current Liabilities for Relay Therapeutics (RLAY) over the last 3 years, with Dec 2023 value amounting to $13.2 million.

  • Relay Therapeutics' Other Non-Current Liabilities fell 63.75% to $11.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.4 million, marking a year-over-year decrease of 63.75%. This contributed to the annual value of $13.2 million for FY2023, which is 59.21% down from last year.
  • As of FY2023, Relay Therapeutics' Other Non-Current Liabilities stood at $13.2 million, which was down 59.21% from $32.4 million recorded in FY2022.
  • In the past 5 years, Relay Therapeutics' Other Non-Current Liabilities ranged from a high of $50.3 million in FY2021 and a low of $13.2 million during FY2023.
  • For the 3-year period, Relay Therapeutics' Other Non-Current Liabilities averaged around $31.9 million, with its median value being $32.4 million (2022).
  • Data for Relay Therapeutics' Other Non-Current Liabilities shows a maximum YoY tumbled of 59.21% (in 2023) over the last 5 years.
  • Relay Therapeutics' Other Non-Current Liabilities (Yearly) stood at $50.3 million in 2021, then plummeted by 35.58% to $32.4 million in 2022, then slumped by 59.21% to $13.2 million in 2023.